Tag
This study reveals how the S1P-TREM2-NRF2 signaling pathway protects tumor-associated neutrophils from ferroptosis, sustaining immunosuppression and promoting hepatocellular carcinoma progression, offering new therapeutic avenues.
Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 can non-invasively predict responses and early resistance to immune checkpoint inhibitors in advanced hepatocellular carcinoma, improving patient stratification and managem
A large multiomic colorectal cancer study identifies CTHRC1-positive fibroblasts as a stromal biomarker linked to TGF-beta activity, adverse outcomes, and reduced checkpoint inhibitor benefit across both MSI and MSS disease.
Researchers discovered that loss of GPRC5D, a key immunotherapy target in multiple myeloma, not only confers resistance to targeted therapies but actively promotes cancer cell proliferation and competitive fitness—creating a therapeutic par
This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with niv
PD-1 inhibitor resistance is a major hurdle in cancer immunotherapy. Six leading combination strategies—including chemotherapy, anti-angiogenic agents, radiotherapy, novel checkpoint inhibitors, microbiome modulation, and ADCs—offer new hop
